Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 603

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Nishio, Makoto, Ponce Aix, Santiago, Paz-Ares, Luis, Chiu, Chao-Hua, Park, Keunchil, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Yoh, Kiyotaka, Shih, Jin-Yuan, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin, Chu, Quincy, Cortot, Alexis, Pujol, Jean-Louis, Moro-Sibilot, Denis, Fabre, Elizabeth, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Engel-Riedel, Walburga, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Takiguchi, Yuichi, Kim, Young Hak, Kurata, Takayasu, Yamaguchi, Hiroyuki, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Kasahara, Kazuo, Atagi, Shinji, Azuma, Koichi, Kumagai, Toru, Aoe, Keisuke, Kumagai, Toru, Aoe, Keisuke, Horio, Yoshitsugu, Yamamoto, Nobuyuki, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Hirashima, Tomonori, Kaneda, Hiroyasu, Tomii, Keisuke, Fujita, Yuka, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Ichiki, Masao, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Park, Keunchil, Kim, Sang-We, Min, Young Joo, Lee, Hyun Woo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Alexandru, Aurelia, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Coves Sarto, Juan, Lin, Meng-Chih, Su, Wu-Chou, Hsia, Te-Chun, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Shih, Jin-Yuan, Su, Jian, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Mileham, Kathryn, Acoba, Jared, Garon, Edward, Jung, Gabriel, Raj, Moses, Martin, William, Dakhil, Shaker · 2019 · The Lancet Oncology

Abstract

BACKGROUND Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC. METHODS This is a worldwide, double-blind, phase 3 trial done in 100 hospitals, clinics, and medical centres in 13 countries. Eligible patients were aged 18 years or older (20 years or older in Japan and Taiwan) at the time of study entry, had stage IV NSCLC, with an EGFR exon 19 deletion (ex19del) or exon 21 substitution (Leu858Arg) mutation, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no CNS metastases. We randomly assigned eligible patients in a 1:1 ratio to receive oral erlotinib (150 mg/day) plus either intravenous ramucirumab (10 mg/kg) or matching placebo once every 2 weeks. Randomisation was done by an interactive web response system with a computer-generated sequence and stratified by sex, geographical region, EGFR mutation type, and EGFR testing method. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov, NCT02411448, and is ongoing for long-term survival follow-up. FINDINGS Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20·7 months (IQR 15·8-27·2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4-21·6]) than in the placebo plus erlotinib group (12·4 months [11·0-13·5]), with a stratified hazard ratio of 0·59 (95% CI 0·46-0·76; p<0·0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]). Treatment-emergent serious adverse events were reported in 65 (29%) of 221 patients in the ramucirumab plus erlotinib group and 47 (21%) of 225 in the placebo plus erlotinib group. The most common serious adverse events of any grade in the ramucirumab plus erlotinib group were pneumonia (seven [3%]) and cellulitis and pneumothorax (four [2%], each); the most common in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]). One on-study treatment-related death due to an adverse event occurred (haemothorax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group. INTERPRETATION Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Safety was consistent with the safety profiles of the individual compounds in advanced lung cancer. The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC. FUNDING Eli Lilly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30634-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 603

Metadata

Authors
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.-H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J.-Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., Reck, M., Chu, Q., Cortot, A., Pujol, J.-L., Moro-Sibilot, D., Fabre, E., Lamour, C., Bischoff, H., Kollmeier, J., Reck, M., Kimmich, M., Engel-Riedel, W., Hammerschmidt, S., Schütte, W., Syrigos, K., Ho, J. C. M., Au, K.-H., Novello, S., Ardizzoni, A., Pasello, G., Gregorc, V., Del Conte, A., Galetta, D., Takahashi, T., Nakagawa, K., Nishio, M., Yoh, K., Seto, T., Imamura, F., Kumagai, T., Hotta, K., Goto, Y., Hosomi, Y., Sakai, H., Takiguchi, Y., Kim, Y. H., Kurata, T., Yamaguchi, H., Daga, H., Okamoto, I., Satouchi, M., Ikeda, S., Kasahara, K., Atagi, S., Azuma, K., Kumagai, T., Aoe, K., Kumagai, T., Aoe, K., Horio, Y., Yamamoto, N., Tanaka, H., Watanabe, S., Nogami, N., Ozaki, T., Koyama, R., Hirashima, T., Kaneda, H., Tomii, K., Fujita, Y., Seike, M., Nishimura, N., Kato, T., Ichiki, M., Saka, H., Hirano, K., Nakahara, Y., Sugawara, S., Park, K., Kim, S.-W., Min, Y. J., Lee, H. W., Kang, J.-H., An, H. J., Lee, K. H., Kim, J.-S., Lee, G.-W., Lee, S. Y., Alexandru, A., Udrea, A. A., Juan-Vidal, Ó., Nadal-Alforja, E., Gil-Bazo, I., Ponce-Aix, S., Paz-Ares, L., Rubio-Viqueira, B., Alonso Garcia, M., Felip Font, E., Fuentes Pradera, J., Coves Sarto, J., Lin, M.-C., Su, W.-C., Hsia, T.-C., Chang, G.-C., Wei, Y.-F., Chiu, C.-H., Shih, J.-Y., Su, J., Cicin, I., Goksel, T., Harputluoglu, H., Ozyilkan, O., Henning, I., Popat, S., Hatcher, O., Mileham, K., Acoba, J., Garon, E., Jung, G., Raj, M., Martin, W., & Dakhil, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-12
Volume
20
Issue
12
Pages
1655-1669
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2978677918
Cited by
603
References
31
FWCI
54.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30634-5
The paper
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.-H., Park, K., Novello, S., Nadal, E., Imamura, F., Yoh, K., Shih, J.-Y., Au, K. H., Moro-Sibilot, D., Enatsu, S., Zimmermann, A., Frimodt-Moller, B., Visseren-Grul, C., . . . Dakhil, S. (2019). Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30634-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.